Home » Drug Information » FDA Approved Drugs » 1996
Medical Areas: Musculoskeletal | Neurology
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Zanaflex (tizanidine hydrochloride)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Elan Pharmaceuticals
Approval Status: Approved December 1996
Treatment Area: muscle spasticity
Zanaflex has been approved as an oral treatment for muscle
spasticity. It is indicated for the management of increased muscle
tone associated with spasticity, a condition affecting the central
nervous system (CNS) causing muscle stiffness and rigidity.
Spasticity can occur as a result of many CNS disorders,
particularly multiple sclerosis ad spinal cord injury.
In double-blind, placebo-controlled clinical studies Zanaflex
was shown to provide significant relief of spasticity symptoms
without causing muscle weakness, which can leave patients unable to
perform normal daily activities. Additionally, reported side
effects did not include evidence of withdrawal effects. Both
weakness and potential withdrawal effects can be characteristic of
certain currently approved treatment regimens.
Spasticity is an abnormal increase in involuntary muscle tone
caused by damage to the CNS and is characterized by painful muscle
spasms as well as muscle stiffness and rigidity. Advanced
spasticity, in the worst cases, can leave patients bed-ridden and
unable to move without assistance.